Compare REGN & CI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | CI |
|---|---|---|
| Founded | 1988 | 1792 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.3B | 78.3B |
| IPO Year | 1995 | 2018 |
| Metric | REGN | CI |
|---|---|---|
| Price | $919.82 | $272.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 24 |
| Target Price | ★ $991.00 | $344.40 |
| AVG Volume (30 Days) | 869.8K | ★ 1.6M |
| Earning Date | 10-30-2026 | 11-05-2026 |
| Dividend Yield | 0.41% | ★ 2.29% |
| EPS Growth | 8.19 | ★ 83.00 |
| EPS | ★ 37.37 | 18.02 |
| Revenue | $5,872,227,000.00 | ★ $274,900,000,000.00 |
| Revenue This Year | $31.18 | $4.99 |
| Revenue Next Year | $7.19 | $3.82 |
| P/E Ratio | $24.71 | ★ $15.15 |
| Revenue Growth | ★ 20.82 | 11.24 |
| 52 Week Low | $591.52 | $257.85 |
| 52 Week High | $991.73 | $318.05 |
| Indicator | REGN | CI |
|---|---|---|
| Relative Strength Index (RSI) | 57.41 | 34.66 |
| Support Level | $735.26 | $267.62 |
| Resistance Level | $986.64 | $274.69 |
| Average True Range (ATR) | 32.57 | 8.91 |
| MACD | -4.43 | -3.60 |
| Stochastic Oscillator | 32.58 | 11.48 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense, and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 16 million US and 2 million international medical members covered as of December 2025.